Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company ...(d by our market research resources...)

by our market research resources that there are approximately two

million bone grafting procedures in the United States every year. The

market for orthopedic biomaterials used in these procedures was

estimated to be approximately $4 billion in 2006. In addition, the

fastest growing segment of this market is recombinant protein products

which is expected to grow to $2.9 billion by 2012.

-- We are developing second-generation technetium-based imaging agents to

aid in the diagnosis of PD, Dementia with Lewy Bodies (DLB), and

Attention Deficit Hyperactivity Disorder (ADHD). We have previously

demonstrated in non-human primate studies that our technetium-based

agents are effective in binding the to DAT in sufficient quantity and

with high-selectivity to provide a readable image in the normal brain.

During 2007, we devised a new radiolabeling procedure for our

technetium agents that results in a high purity, high yield product as

a prelude to obtaining definitive images in non-human primates.

Continued Intellectual Property (IP) leadership notably in regenerative

therapeutics.

Alseres' IP portfolio includes issued, allowed or granted patents from the

U.S. and other key countries worldwide. During 2007, the company

submitted 14 new patent applications covering our regenerative

therapeutics, molecular imaging, and neurodegenerative disease assets. We

were granted three new patents covering CETHRIN, four additional patents

covering other regenerative therapies and one patent covering our DAT

blocker platform.

Business & Operational Highlights

Licensed Phase I/IIa Regenerative Therapeutics Program in acute SCI.

In December 2006, Alseres licensed, from BioAxone Therapeutic, Inc. of

Montreal, Canada, development and commercialization rights of CETHRIN, as